Drug-Induced Conditioned Place Preference and Its Practical Use in Substance Use Disorder Research

McKendrick, Greer; Graziane, Nicholas

doi:10.3389/fnbeh.2020.582147

Cited by 109 publications

(66 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While self-administration studies of SI 1/28 were beyond the scope of the current study, potential rewarding effects were evaluated in the CPP assay. Unlike morphine, which displayed typical rewarding effects in CPP [ 48 , 49 ], SI 1/28 did not produce conditioned place preference. These effects were in accordance with literature demonstrating that S1R antagonists produce neither conditioned place preference nor conditioned place aversion [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Wilson

Eans

Ramadan-Siraj

et al. 2022

IJMS

View full text Add to dashboard Cite

Neuropathic pain is a significant problem with few effective treatments lacking adverse effects. The sigma-1 receptor (S1R) is a potential therapeutic target for neuropathic pain, as antagonists for this receptor effectively ameliorate pain in both preclinical and clinical studies. The current research examines the antinociceptive and anti-allodynic efficacy of SI 1/28, a recently reported benzylpiperazine derivative and analog of the S1R antagonist SI 1/13, that was 423-fold more selective for S1R over the sigma-2 receptor (S2R). In addition, possible liabilities of respiration, sedation, and drug reinforcement caused by SI 1/28 have been evaluated. Inflammatory and chemical nociception, chronic nerve constriction injury (CCI) induced mechanical allodynia, and adverse effects of sedation in a rotarod assay, conditioned place preference (CPP), and changes in breath rate and locomotor activity were assessed after i.p. administration of SI 1/28. Pretreatment with SI 1/28 produced dose-dependent antinociception in the formalin test, with an ED50 (and 95% C.I.) value of 13.2 (7.42–28.3) mg/kg, i.p. Likewise, SI 1/28 produced dose-dependent antinociception against visceral nociception and anti-allodynia against CCI-induced neuropathic pain. SI 1/28 demonstrated no impairment of locomotor activity, conditioned place preference, or respiratory depression. In summary, SI 1/28 proved efficacious in the treatment of acute inflammatory pain and chronic neuropathy without liabilities at therapeutic doses, supporting the development of S1R antagonists as therapeutics for chronic pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Wilson

Eans

Ramadan-Siraj

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…To assess whether DCZ is intrinsically rewarding or aversive we used a place conditioning assay to determine whether repeated injections of DCZ paired with a distinct context could produce a place preference/aversion (Cunningham et al, 2006;McKendrick & Graziane, 2020). The results of these experiments revealed that DCZ did not support a conditioned place preference or aversion of the DCZ-paired compartment.…”

Section: Discussionmentioning

confidence: 99%

Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats

Nentwig

Obray

Vaughan

et al. 2021

Preprint

View full text Add to dashboard Cite

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) have become a premier neuroscience research tool in the past decade for their utility in providing reversible manipulations of cellular activity following experimenter-controlled delivery of a DREADD-specific ligand. However, the commonly used DREADD ligand, clozapine-N- oxide (CNO), has metabolic and off-target effects that may confound experimental results and interpretations. Moreover, CNO has relatively poor affinity for DREADD receptors, which necessitates high doses for systemic administration applications. New DREADD ligands aim to reduce metabolic and potential off-target effects while maintaining strong efficacy for the designer receptors. Recently a novel DREADD ligand, deschloroclozapine (DCZ), was shown to induce chemogenetic-mediated cellular and behavioral effects in mice and monkeys without detectable side effects. While promising, further testing of DCZ across species and experimental paradigms is warranted. The goal of the present study was to examine the effectiveness of systemic DCZ for DREADD-based chemogenetic manipulations in behavioral and slice electrophysiological applications in rats. We demonstrate that a relatively low dose of DCZ (0.1 mg/kg) supports excitatory DREADD- mediated cFos induction, DREADD-mediated inhibition of a central amygdala-dependent behavior, and DREADD-mediated inhibition of neuronal activity in a slice electrophysiology preparation. In addition, we show that this dose of DCZ does not alter gross locomotor activity or induce a place preference/aversion in control rats without DREADD expression. Together, our findings support the use of systemic DCZ for DREADD-based manipulations in rats, and provide evidence that DCZ is a superior alternative to CNO.

show abstract

“…The conditioned place preference (CPP) model is a well-established paradigm that can be used to evaluate the transition from a neutral stimulus to a conditioned stimulus in reward-related behaviors, driving a conditioned response (i.e. behaviors of approaching a drug-paired environmental context) [ 23 , 24 ]. In this model, animals are confined to two distinct environmental contexts, one of which is paired with the rewarding state produced by the drug of abuse.…”

Section: Introductionmentioning

confidence: 99%

The distinct roles of various neurotransmitters in modulating methamphetamine-induced conditioned place preference in relevant brain regions in mice

Bai

Fan

et al. 2021

NeuroReport

View full text Add to dashboard Cite

Objectives Previous studies have shown that methamphetamine (METH) can induce complex adaptive changes in the reward system in the brain, including the changes in the content of neurotransmitters in the signal transduction pathway. However, how the changes of various neurotransmitters in relevant brain reward circuits contribute to METH-induced conditioned place preference (CPP) remains unclear.Methods In this study, first, we designed an animal model of METH-induced CPP. Then we used liquid chromatography-mass spectrometry (LC-MS) to simultaneously determine the contents of various neurotransmitters -dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT), 5-hydroxyindole acetic acid (5-HIAA), glutamic acid (Glu) and glutamine (Gln) -in different brain regions of the prefrontal cortex (PFc), nucleus accumbens (NAc), caudate-putamen (CPu) and hippocampus (Hip), which are believed to be relevant to the drug's reward effect. ResultsThe results of the behavioral experiment suggested that 1.0 mg/kg METH could induce obvious CPP in mice. The results about various neurotransmitters showed that: DA significantly increased in NAc in the METH group; Glu increased significantly in the METH group in PFc and NAc and Gln increased significantly in the METH group in PFc. ConclusionsThese results suggested that the neurotransmitters of DA, Glu and Gln may work together and play important roles in METH-induced CPP in relevant brain reward circuits, especially in PFc and NAc. These findings therefore could help to advance the comprehensive understanding of the neurochemic and psychopharmacologic properties of METH in reward effect, which is important for future improvements in the treatment of drug addiction.

show abstract

Drug-Induced Conditioned Place Preference and Its Practical Use in Substance Use Disorder Research

Cited by 109 publications

References 219 publications

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats

The distinct roles of various neurotransmitters in modulating methamphetamine-induced conditioned place preference in relevant brain regions in mice

Contact Info

Product

Resources

About